G1 Therapeutics (GTHX)
(Delayed Data from NSDQ)
$7.08 USD
-0.01 (-0.14%)
Updated Aug 13, 2024 04:00 PM ET
After-Market: $7.08 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth A Momentum F VGM
Brokerage Reports
G1 Therapeutics [GTHX]
Reports for Purchase
Showing records 281 - 300 ( 357 total )
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Trila Moving Towards Market with Q4:19 NDA Submission, Lero Data Up Next
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
EMSO 2019 Abstract Roundup for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
ESMO Preview: Ramblin? on at Las Ramblas with Across the Board Data Updates
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
HCW Global Investment Conference; New Data at ESMO 2019 in Late September
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
2Q19 Results; Data for All Three Programs at ESMO; Trilaciclib Receives Breakthrough Therapy Designation
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
BTD for Trila and Pivoting for More Pivotal Trials in 2020
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Statistically Significant Overall Survival Reported for Trilaciblib in Metastatic Triple-Negative Breast Cancer
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Biotechnology - ASCO Roundup for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Biotechnology- ASCO Abstract Roundup for Covered Companies
Provider: WEDBUSH SECURITIES INC.